05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Poultices, pharmaceutical preparations for the treatment of pain, central nervous system disorders, and dermatological conditions; reagent paper for medical purposes, oiled paper for medical purposes, adhesive tapes for medical purposes, wrapping wafers for medicine doses being drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals, gauze for dressings, empty capsules for pharmaceuticals, eyepatches for medical purposes, ear bandages, menstruation bandages, menstruation tampons, sanitary napkins, sanitary panties, absorbent cotton for medical purposes, adhesive plasters for medical purposes, bandages for dressings, antiseptic liquid bandages, breast-nursing pads, cotton swabs for medical use, dental impression materials, fly catching paper, mothproofing paper
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Poultices, pharmaceutical preparations for the treatment of pain, central nervous system disorders, and dermatological conditions; reagent paper for medical purposes, oiled paper for medical purposes, adhesive tapes for medical purposes, wrapping wafers for medicine doses being drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals, gauze for dressings, empty capsules for pharmaceuticals, eyepatches for medical purposes, ear bandages, menstruation bandages, menstruation tampons, sanitary napkins, sanitary panties, absorbent cotton for medical purposes, adhesive plasters for medical purposes, bandages for dressings, antiseptic liquid bandages, breast-nursing pads, cotton swabs for medical use, dental impression materials, fly catching paper, mothproofing paper
4.
LOXOPROFEN-CONTAINING ADHESIVE PATCH AND METHOD FOR MANUFACTURING SAME
The present invention provides a patch that suppresses the generation of a degradation product of loxoprofen and shows excellent skin permeability, and a method for producing the same. Specifically, the present invention provides a patch comprising loxoprofen or a salt thereof, or a hydrate thereof; a C2-C6 hydroxy acid; and a metal oxide in a pasty preparation, and a method for producing the same.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
The present invention provides a transdermally absorbable preparation which demonstrates the same level of pharmacokinetics and therapeutic effect as does orally administered donepezil. The present invention specifically provides a transdermally absorbable preparation for treating dementia which has an adhesive layer containing donepezil free base, said adhesive layer containing a styrene-isoprene-styrene block copolymer and 13.75 -55mg of donepezil free base. The preparation is to be administered to a patient once per day.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention provides a patch which prevents ketoprofen from forming a menthol ester, suppresses crystal precipitation, and yet shows excellent skin permeability. Specifically, the present invention provides a patch comprising ketoprofen, L-menthol, zinc oxide, and a fatty acid ester in a pasty preparation.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations in the nature of topical and oral preparations, transdermal patches, medical dressings and medical adhesive tapes for treating cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, vitamin imbalance, gastrointestinal conditions, inflammation, skin conditions, infectious diseases, asthma, hormonal imbalance and pain; dietary and nutritional supplements; laxative suppositories; enema preparations
The purpose of the present invention is to provide an aqueous patch in which basic physical properties as an aqueous patch are less likely to deteriorate and crystals of 1-menthol are less likely to precipitate. The aqueous patch includes, in a pasty preparation, 1-menthol: 0.5% by mass or more and 10% by mass or less, an oil component: 0.2% by mass or more and 19% by mass or less; and silica: 0.1% by mass or more and 5.5% by mass or less.
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
10.
LOXOPROFEN-CONTAINING ADHESIVE PATCH AND METHOD FOR MANUFACTURING SAME
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention provides a patch that prevents ketoprofen from forming menthol ester, suppresses crystal deposition and yet shows excellent skin permeability. More particularly, the present invention provides a patch that contains ketoprofen, L-menthol, zinc oxide and a fatty acid ester in a plaster.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The purpose of the present invention is to provide a rivastigmine-containing transdermal absorption preparation having high adhesion to the skin and capable of continuously administering rivastigmine over a long period of time. A transdermal absorption preparation has rivastigmine, a rubber polymer, a tackifier resin, and a polymer compound having a nitrogen-containing group.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
Provided is a water-based adhesive patch which has basic physical properties required of a water-based adhesive patch that are less apt to deteriorate and in which crystals of l-menthol are less apt to separate out. This water-based adhesive patch includes a plaster which contains 0.5-10 mass% l-menthol, 0.2-19 mass% oil, and 0.1-5.5 mass% silica.
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
The present invention provides a testosterone-containing transdermal formulation having excellent skin permeability of testosterone and excellent formulation properties. Specifically, the present invention provides a transdermal formulation comprising testosterone; polyacrylic acid or a salt thereof; a thickener; a cross-linking agent; a plasticizer comprising propylene glycol; and a lactic acid ester in a pasty preparation.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/568 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
10 - Appareils et instruments médicaux
11 - Appareils de contrôle de l'environnement
Produits et services
Cosmetics; skin sheet masks for cosmetic use; beauty masks; cosmetic facial masks; cosmetic masks Cooling sheets for medical purposes applied to affected areas Chemically-activated cooling sheets for cooling the body and not for medical purposes
The present invention provides a risperidone-containing patch having an excellent drug release property and patch physical properties. Specifically, the present invention provides a medical patch comprising an adhesive composition comprising risperidone or a pharmaceutically acceptable salt thereof; a carboxylic acid; a fatty acid ester; and an adhesive, characterized in that said adhesive is a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a sulfur residue of a mercapto group situated at the center, wherein the (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.99% by mass of the whole structural units in said star-shaped acrylic block polymer, and at least one of said chain polymer portions has a structural unit having a copolymer structure of polymerizable monomers comprising a (meth)acrylic acid alkyl ester having 7-17 carbon atoms and a polyfunctional monomer.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 31/194 - Acides carboxyliques, p. ex. acide valproïque ayant plusieurs groupes carboxyle, p. ex. acides succinique, maléique ou phtalique
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Cosmetics. Prescription and over-the-counter pharmaceutical
preparations, namely topical formulations, transdermal
patches, dressings and medical tapes for use with humans and
animals.
The present invention provides an aqueous patch which can stably contain only one of an S-enantiomer and an R-enantiomer of a drug capable of being present in such enantiomers at a relatively high concentration over a long period of time, has the excellent adhesive property and the excellent shape retaining property, and achieves high skin permeability of the drug. Specifically, the present invention provides an aqueous patch containing only one of enantiomers of a drug as an active ingredient in a pasty preparation.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Cosmetics Prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, topical formulations for treatment of inflammation; prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, transdermal patches for treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, vitamin imbalance, gastrointestinal conditions, skin conditions, infectious diseases, asthma, hormonal imbalance, and pain; prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, medical and surgical dressings; prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, medical adhesive tapes
The present invention provides a testosterone-containing transdermally administrable preparation having excellent testosterone cutaneous permeability and excellent physical properties. More specifically, the present invention provides a transdermally administrable preparation which contains testosterone, a polyacrylic acid or a salt thereof, a thickening agent, a cross-linking agent, a plasticizer containing propylene glycol and a lactic acid ester in a plaster.
A61K 31/568 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61P 5/50 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques pour augmenter ou potentialiser l'activité de l'insuline
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 15/10 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour l'impuissance
A61P 15/12 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour la ménopause
A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Provided is a rivastigmine-containing percutaneous absorption-type preparation which has high adhesion to skin and which allows rivastigmine to be sustainably administered for a long period of time. The percutaneous absorption-type preparation is characterized by containing a polymer compound having rivastigmine, a rubber polymer, tackifying resin, and a nitrogen-containing group.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A receiving container includes a container body and a grip member. The container body includes: a body portion in a hollow tubular shape; a bottom portion configured to close one end side opening portion of the body portion; and a ceiling portion configured to close another end side opening portion of the body portion. One of a first extending portion and a second extending portion of the ceiling portion has a separation portion configured to separate a tip portion. The grip member includes: attachment portions, and a grip portion grippable by hand. The attachment portions are configured to prevent the first extending portion and the second extending portion from opening from the other end side opening portion. The attachment portions are attached to a tip side of the separation portion in either of the first or second extending portion provided with the separation portion.
B65D 5/54 - Lignes de moindre résistance facilitant l'ouverture des réceptacles ou leur division en parties séparées, par découpage ou déchirement
B65D 5/02 - Réceptacles de section transversale polygonale rigides ou semi-rigides, p. ex. boîtes, cartons ou plateaux, formés en pliant ou montant un ou plusieurs flans de papier en pliant ou montant un seul flan pour former un corps tubulaire avec ou sans pliage subséquent, ou par addition d'éléments séparés, pour fermer les extrémités du corps
An external patch that contains rupatadine as a second-generation antihistamine, has excellent plaster physical properties, good adhesion to applied skin, and good transdermal absorption of rupatadine as an active ingredient is provided. The external patch containing rupatadine uses an acrylic adhesive as an adhesive base. Specifically, the external patch containing rupatadine uses an acrylic adhesive as an adhesive base and further contains an organic acid having 2 to 7 carbon atoms as a solubilizer, a fatty acid ester as a softener, and/or a surfactant.
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61P 11/02 - Agents rhinologiques, p. ex. décongestionnants
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention provides a risperidone-containing patch endowed with both excellent drug releasability and patch physical properties. Specifically, the present invention provides a medical patch that includes risperidone or a pharmaceutically acceptable salt thereof, a carboxylic acid, a fatty acid ester, and an adhesive composition including an adhesive, wherein the medical patch is characterized in that the adhesive is a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain-form polymer moieties extend radially from a sulfur residue of a mercapto group in the center, 30-99.99 mass% of the total structural units of the star-shaped acrylic block polymer are C7-17 (meth)acrylic acid alkyl ester units, and at least one of the chain-form polymer moieties is a structural unit having a copolymer structure of a C7-17 (meth)acrylic acid alkyl ester and a polymerizable monomer including a polyfunctional monomer.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
The present invention provides a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a mercapto group situated at the center, wherein (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.9% by mass of whole structural units of the star-shaped acrylic block polymer, and at least one of the chain polymer portions has a copolymer structure of polymerizable monomers containing a (meth)acrylic acid alkyl ester having 7-17 carbon atoms and a weakly basic monomer; and a medical patch containing an adhesive composition containing a salt of a basic drug and the star-shaped acrylic block polymer as an adhesive that exhibits high drug efficacy, that does not cause a decrease in adhesive property of an adhesive base due to an additive, and that causes less skin irritation.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
C09J 7/20 - Adhésifs sous forme de films ou de pellicules caractérisés par leur support
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Provided is a transdermal preparation containing rivastigmine, which is capable of continuously administering an active ingredient that is rivastigmine for a long time, and which has low skin irritancy. A transdermal preparation according to the present invention contains, in mass%, from 5% to 30% (inclusive) of rivastigmine, from 10% to 60% (inclusive) of a rubber adhesive and from 30% to 70% (inclusive) of a tackifying resin; and if a (%) is the content of the rivastigmine, b (%) is the content of the rubber adhesive and c (%) is the content of the tackifying resin, a, b and c satisfy formulae (1) and (2). a + c ≥ 55 (1) b/c ≤ 1.00 (2)
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p. ex. peau, os, lait, fibre de coton, coquille d’œuf, fiel de bœuf ou extraits de plante
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Provided is an adhesive patch containing ropinirole serving as a therapeutic drug for Parkinson's disease, with the ropinirole used being free ropinirole (ropinirole in free form) added to an adhesive base, wherein the patch exhibits favorable drug permeability and excellent drug stability. Also provided is a transdermal absorption patch using, as an adhesive base, an acrylic-based adhesive having no specific carboxyl group and having a hydroxyl group or a pyrrolidone group, with the patch including free ropinirole added to the adhesive base. Further provided is a ropinirole-containing transdermal absorption patch including a transdermal absorption promoting agent.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
A61K 31/4166 - 1,3-Diazoles ayant des groupes oxo liés directement à l'hétérocycle, p. ex. phénytoïne
A61K 31/473 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. acridines, phénantridines
A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
The present invention provides a water-based adhesive patch which can stably contain only one of the optical isomers, S- and R-isomers, of a drug in a relatively high concentration over a long period and which has excellent tackiness and shape retentivity and, despite this, enables the drug to highly permeate the skin. Specifically, the present invention provides a water-based adhesive patch including a plaster which contains only one of the optical isomers of a drug as an active ingredient.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The purpose of the present invention is to provide a transdermal absorption-type patch preparation comprising zonisamide, said transdermal absorption-type patch preparation comprising zonisamide or an alkali metal salt thereof as zonisamide or an alkali metal salt thereof, being capable of holding a high concentration of the drug in a dissolved state therein and exerting a sufficient and long-lasting drug effect. A transdermal absorption-type patch preparation that comprises an adhesive layer, said adhesive layer comprising zonisamide or an alkali metal salt thereof, an adhesive agent comprising a (meth)acrylic copolymer having a pyrrolidone group, and a transdermal absorption promoter comprising an N-alkylpyrrolidone.
A61K 31/423 - Oxazoles condensés avec des carbocycles
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention provides: a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a mercapto group situated at the center, wherein (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.9 mass% of all structural units of the star-shaped acrylic block polymer, and at least one of the chain polymer portions has a copolymer structure of polymerizable monomers including a weak basic monomer and (meth)acrylic acid alkyl ester having 7-17 carbon atoms; and a medical adhesive patch that exhibits high efficacy, that causes less skin irritation and does not cause a decrease in adhesive properties of the adhesive base due to additives, and that contains a salt of a basic drug and an adhesive agent composition containing the star-shaped acrylic block polymer as an adhesive agent.
C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
Provided is a novel transdermal absorption preparation containing silodosin or tamsulosin, or salt thereof as an active ingredient, wherein the transdermal absorption preparation is capable of keeping a dissolved state for a long time, as well as has a high permeability to a skin, and can effectively and sustainably exert the transdermal absorbability. A transdermal absorption preparation containing the transdermal absorption preparation comprises an acrylic pressure-sensitive adhesive that comprises a copolymer of at least one (meth)acrylic acid monomer and at least one vinyl monomer and that contains a carboxyl group, and at least one transdermal absorption promoting agent selected from the group consisting of oleyl alcohol, lauryl alcohol, and lauromacrogol.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A patch for external use which has a laminate structure comprising a substrate and a pressure-sensitive adhesive layer which contains a styrene/isoprene/styrene block copolymer as the base and further contains a tackifier resin consisting of a rosin resin and at least one other tackifier resin, a softening agent consisting of polybutene and liquid paraffin, a fatty acid ester, and fentanyl, characterized in that the weight ratio of the rosin resin to fentanyl is 1 to 5, the weight ratio of the rosin resin to the whole tackifier resin is 0.1 to 0.6, and the tackifier resin accounts for 30 to 60 wt % of the whole pressure-sensitive adhesive layer. The patch is excellent in the permeation of fentanyl through the skin and in storage stability, and is weak in irritation to skin.
A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The present invention is provided with a container body 4 and a grip member 5. The container body 4 has a hollow cylindrical trunk part 1, a bottom part 2 for closing off a one-end-side opening of the trunk part 1, and a top part 3 for closing off an other-end-side opening of the trunk part 1. The top part 3 has a first extending part 17d and a second extending part 17b extending from the edges of the other-end-side opening. A separation part 25 for detaching a distal-end portion is formed on the first extending part 17d or the second extending part 17b. The grip member 5 has attachment parts 31 and a grip part 30 that can be manually gripped. The attachment parts 31 prevent the first extending part 17d and the second extending part 17b from opening from the other-end-side opening. The attachment parts 31 are attached to the extending part 17b or 17d on which the separation part 25 is formed, the attachment parts 31 being closer to the distal end than is the separation part 25.
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Cosmetics. Prescription and over-the-counter pharmaceutical
preparations, namely topical formulations, transdermal
patches, dressings and medical tapes for use with humans and
animals.
Provided is a patch preparation that has improved adhesion to an adherend so as to enable a drug, especially, a systemically active drug to be stably and continuously administered over an extended period. The patch preparation has a layered structure comprising a patch layer including an adhesive plaster containing a drug and a patch support, and a cover layer in this order from a side attached to a skin. In the patch preparation, a buffer material is disposed between the patch support of the patch layer and the cover layer, the cover layer has a size covering an area beyond peripheral edges of the patch layer, and a shielding film is further disposed between the cover layer and the buffer material.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
[ Cosmetics ] [ Prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, topical formulations for treatment of inflammation; ] Prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, transdermal patches for treatment of [ cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, vitamin imbalance, gastrointestinal conditions, skin conditions, infectious diseases, asthma, hormonal imbalance, and ] pain [ ; Prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, medical and surgical dressings; Prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, medical adhesive tapes ]
39.
Fentanyl-containing adhesive preparation for external use
Disclosed is a fentanyl-containing adhesive preparation for external use, wherein an adhesive layer is laminated on a supporting body. The adhesive layer contains SIS, a tackifier resin that is composed of a rosin resin and terpene resin, and a softener that is composed of a plybutene and a liquid paraffin. The adhesive layer also contains fentanyl as an active ingredient. The fentanyl-containing adhesive preparation for external use has excellent skin permeation of fentanyl and high preparation stability, without suffering from crystallization of fentanyl during storage.
The present invention provides a patch containing beraprost or a pharmacologically acceptable salt thereof, which achieves high transdermal absorption of beraprost or a pharmacologically acceptable salt thereof and has excellent formulation properties.
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 31/5585 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes ayant des cycles à cinq chaînons contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. prostacycline
Provided is a novel transdermal preparation which contains, as an active ingredient, silodosin, a salt of silodosin, tamsulosin or a salt of tamsulosin, and which is capable of maintaining a dissolved state for a long period of time and has excellent skin permeability, while exhibiting percutaneous absorption effectively and continuously. A transdermal preparation which contains: an acrylic adhesive containing an acrylic copolymer which is a copolymer of at least one (meth)acrylic acid monomer and at least one vinyl monomer, and which contains a carboxyl group; and at least one percutaneous absorption enhancer that is selected from the group consisting of oleyl alcohol, lauryl alcohol and lauromacrogol.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A patch containing free ropinirole (ropinirole in free form) in an adhesive base is provided, in which the patch exhibits favorable and continuous transdermal absorbability, high drug stability, and excellent adhesiveness. A transdermal absorption patch includes free ropinirole added to an adhesive base that contains a styrene-isoprene-styrene block copolymer (SIS), one or two or more tackifier resins containing a rosin-based resin, and a softener. The transdermal absorption patch is characterized in that the compounding ratio of the rosin-based resin to the free ropinirole represented as the ratio of the weight of the combined rosin-based resin to the free ropinirole is 3.5 to 8.0. In particular, a ropinirole-containing patch wherein the rosin-based resin is a hydrogenated rosin glycerol ester and the softener is liquid paraffin is provided.
Provided is a patch preparation having improved adhesion to an adherend so as to be able to continuously administer a drug, particularly a drug having systemic action, in a consistent fashion for an extended period. The patch preparation has a laminated structure comprising, in order from the skin-adhering side: an adhesive patch layer comprising a pressure-sensitive plaster containing a drug, and an adhesive patch support; and a cover layer, wherein the patch preparation is characterized in that a cushioning material is arranged between the cover layer and the adhesive patch support of the adhesive patch layer, the cover layer being of a size covering an area beyond the peripheral edges of the adhesive patch layer, and a masking film is further arranged between the cover layer and the cushioning material.
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer. In some instances, the matrix further includes a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
Iontophoretic devices for transdermal delivery of a sphingosine-1-phosphate receptor agonist active agent are provided. Also provided are methods of transdermally delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat immune system disorders such as multiple sclerosis. Packaged iontophoretic systems, kits including iontophoretic devices, and methods of making iontophoretic devices are also provided.
A transdermal absorption preparation comprising (1) a support, and (2) a rubber-based adhesive layer comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof, oleic acid, capric acid and crotamiton, wherein the rubber-based adhesive layer is formed on a surface of the support. The transdermal absorption preparation exhibits excellent transdermal absorption of the 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or salt thereof.
The present invention provides a patch containing beraprost or a pharmacologically acceptable salt thereof and having excellent percutaneous absorption of beraprost or a pharmacologically acceptable salt thereof and good formulation properties.
A61K 31/5585 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes ayant des cycles à cinq chaînons contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. prostacycline
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention provides a tolterodine-containing patch in which an adhesive layer is laminated on a backing, characterized in that the adhesive layer is obtainable by adding tolterodine to an adhesive base comprising a rubber adhesive, a tackifier resin, and a softener, wherein the tolterodine is present in the form of a free base in the adhesive base.
A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
Provided is an adhesive patch containing ropinirole serving as a therapeutic drug for Parkinson's disease, with the ropinirole used being free ropinirole (ropinirole in free form) added to an adhesive base, wherein the patch exhibits favorable drug permeability and excellent drug stability. Also provided is a transdermal absorption patch using, as an adhesive base, an acrylic-based adhesive having no specific carboxyl group and having a hydroxyl group or a pyrrolidone group, with the patch including free ropinirole added to the adhesive base. Further provided is a ropinirole-containing transdermal absorption patch including a transdermal absorption promoting agent.
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
51.
Extended buprenorphine transdermal delivery compositions and methods for using the same
Aspects of the invention include extended transdermal delivery devices for delivering buprenorphine to a subject for an extended period of time, where the transdermal delivery devices include buprenorphine, an α-hydroxy acid and a pressure sensitive adhesive. In certain instances, buprenorphine, α-hydroxy acid and the pressure sensitive adhesive are provided as a single matrix layer formulation. Also provided are methods of using the subject extended transdermal delivery devices, as well as kits containing the extended transdermal delivery device.
An iontophoresis patch (12) which outputs an electric current from an energizing device (14) to an external conductor comprises: a donor portion (16) that has a first contact member (34); a reference portion (18) that has a second contact member (38) and is located on the external conductor away from the donor portion (16); and an electrode body (20) that has a first electrode (42, 70, 80, 90) and a second electrode (44) and that extends across the donor portion (16) and the reference portion (18). The electrode body (20) has a single-sided wiring structure in which the first electrode (42, 70, 80, 90) and the second electrode (44) are formed by a conductive ink being printed on one side of a film (28), the printing pattern of the first electrode (42) has a gap area (43, 71, 81, 91) in which the conductive ink is not printed, and the film (28) and the first contact member (34) are transparent.
Provided is a transdermal absorption-type patch containing a serotonin receptor antagonist, which has a short transdermal absorption delay time (lag time), and in which the maximum transdermal permeation rate of the drug can be reached within a short time and the drug can disappear from circulating blood rapidly. That is, provided is a patch containing a serotonin receptor antagonist, wherein the patch contains an adhesive layer comprising a non-functional acrylic adhesive, a water-soluble organic amine, a fatty acid ester, and a serotonin receptor antagonist such as granisetron as an active ingredient.
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
Provided is a water-based plaster in which the gel strength is maintained to an appropriate level in a step of producing the water-based plaster, and particularly in a spreading step and an aging step, and a final preparation can exhibit an optimal adhesiveness for adhering to the skin. In the water-based plaster, a water-based adhesive base containing a water-soluble polymer as a main ingredient contains a higher fatty acid which is a liquid at room temperature and a viscosity of 1,000 (mPa·s, 20° C.) or more as a crosslinking modifier. The higher fatty acid is isostearic acid, and the contained amount thereof is 1 to 10% by weight.
The purpose of the present invention is to provide an adhesive patch that is obtained by blending ropinirole, which is in a free form, in an adhesive base, said adhesive patch having good and lasting percutaneous absorption, excellent medicinal ingredient stability and excellent adhesiveness. Provided is a transdermal adhesive patch that is obtained by blending ropinirole, which is in a free form, in an adhesive base that is obtained by compounding a styrene-isoprene-styrene block copolymer (SIS), a softening agent and one or more kinds of tackifying resins each containing a rosin resin. This transdermal adhesive patch is characterized in that the blending ratio of the rosin resin to the ropinirole in a free form, namely (the blending weight of the rosin resin)/(the ropinirole in a free form) is 3.5-8.0. In particular, a ropinirole-containing adhesive patch wherein the rosin resin is a hydrogenated rosin glycerol ester and the softening agent is a liquid paraffin.
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention verifies a method of reducing skin irritation (particularly, cumulative skin irritation) caused by transdermal administration of a local anesthetic using iontophoresis, and provides an electrode pad for relief from a puncture pain which is safe not only at single administration but also at repeated administrations. The electrode pad comprises a base sheet; an electrode placed on the base sheet; an adhesive sheet placed on the base sheet and having an opening, within which the electrode being exposed; and a medicament reservoir containing a local anesthetic and placed in the opening of the adhesive sheet while being in contact with the electrode. An inner peripheral surface of the opening of the adhesive sheet and an outer peripheral surface of the medicament reservoir are prevented from coming into contact with human skin while contacting with each other, and thereby skin irritation is reduced.
A61N 1/32 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents
A61N 1/30 - Appareils d'ionothérapie ou d'électrophorèse
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
Methods of treating skin neoplasms using a monoamine oxidase inhibitor, e.g., a propynylaminoindan (such as rasagiline) are provided. Pharmaceutical compositions and kits comprising monoamine oxidase inhibitors are also provided.
[Problem] To provide a transdermal absorption preparation exhibiting excellent transdermal absorption performance for 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof. [Solution] A transdermal absorption preparation having a support, and a rubber-based adhesive layer that is formed on the surface of the support and contains 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof, the rubber-based adhesive layer further containing oleic acid, capric acid, and crotamiton.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61P 13/02 - Médicaments pour le traitement des troubles du système urinaire de l'urine ou des voies urinaires, p. ex. acidificateurs d'urine
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
Provided is a felbinac-containing external patch which can exhibit high drug release properties, low skin irritation, and high drug stability, wherein felbinac having an average particle diameter of 5 μm or more and less than 100 μm is dispersed and mixed in an adhesive base including a styrene-isoprene-styrene block copolymer, an alicyclic saturated hydrocarbon resin, a softener, and diethyl sebacate, and does not contain L-menthol. Specifically, in the felbinac-containing external patch, 0.1 to 10% by weight of felbinac having an average particle diameter of 5 μm or more and less than 100 μm is dispersed and mixed in an adhesive base including 10 to 30% by weight of a styrene-isoprene-styrene block copolymer, 10 to 50% by weight of an alicyclic saturated hydrocarbon resin, 10 to 75% by weight of a softener, and 0.1 to 10% by weight of diethyl sebacate.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
69.
Method for using hydrogel sheet for treating wound
A61F 13/00 - Bandages ou pansementsGarnitures absorbantes
A61L 15/26 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carboneLeurs dérivés
A61L 15/60 - Matériaux gonflant avec les liquides pour former un gel, p. ex. super-absorbants
A61L 15/46 - Désodorisants ou produits pour neutraliser les mauvaises odeurs, p. ex. pour inhiber la formation d'ammoniac ou la multiplication de bactéries
The present invention provides a tolterodine-containing adhesive patch, which is an adhesive patch obtained by laminating an adhesive layer on a supporting body, and which is characterized in that the adhesive layer is obtained by blending tolterodine into an adhesive base material that contains a rubber-based adhesive, an adhesiveness-imparting resin and a softening agent. In this tolterodine-containing adhesive patch, the tolterodine is present in the adhesive base material in the form of a free base.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
Provided is an adhesive patch with ropinirole, which is a therapeutic drug for Parkinson's disease, formulated in a pressure-sensitive adhesive base while still in a free form, the adhesive patch exhibiting favorable drug permeability and excellent drug stability. The ropinirole-containing transdermal absorption adhesive patch is formulated with a transdermal absorption enhancer, the transdermal absorption adhesive patch characterized in that a specific acrylic pressure-sensitive adhesive having no carboxyl groups and having either a hydroxyl group or a pyrrolidone group is used as a pressure-sensitive adhesive base, and a free form of ropinirole is formulated in the pressure-sensitive adhesive base.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
[Problem] To provide a transdermally absorbed preparation having excellent transdermal absorbability of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof contained therein. [Solution] A transdermally absorbed preparation comprising a support and an acrylic adhesive agent layer that is formed on the surface of the support and contains 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof, wherein the acrylic adhesive agent layer additionally contains oleic acid and a carboxylic acid having 2-10 carbon atoms.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61P 13/10 - Médicaments pour le traitement des troubles du système urinaire de la vessie
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
73.
Transdermal compositions comprising an active agent layer and an active agent conversion layer
Transdermal compositions are provided. Aspects of the transdermal compositions include: an active agent layer and a conversion layer, where the conversion layer includes a weak base and, optionally, a carboxylated component. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
An adhesive patch is a felbinac-containing transdermally absorbable preparation substantially free of a solubilizer for felbinac in a final preparation but still having high releasing of felbinac. The adhesive patch in which lidocaine and felbinac are formulated has the releasing of felbinac without losing the releasing of lidocaine. The felbinac-containing transdermally absorbable adhesive patch contains felbinac as an active component and lidocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In particular, the content of felbinac is from 0.1% to 10% by weight to the total weight of the drug-containing plaster and the content of lidocaine or the pharmaceutically acceptable salt thereof is from 0.01% to 20% by weight to the total weight of the drug-containing plaster.
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
Provided is a water-based plaster whereby the gel strength of a water-based adhesive base can be retained in an appropriate state during the steps for producing the water-based plaster, in particular a spreading step and conditioning step, and whereby an optimal adhesiveness for adhering to the skin can be exhibited in a final preparation. The present invention is a water-based plaster, characterized in that a water-based adhesive base in which the main ingredient is a water-soluble polymer contains, as a crosslinking modifier, a higher fatty acid which is liquid at room temperature and has a viscosity of 1000 (mPa·s, 20°C) or higher, wherein the higher fatty acid is isostearic acid and the formulated amount thereof is 1-10 wt%.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
Provided is a loxoprofen sodium-containing adhesive patch for external applications, which has high transdermal absorbability of the main ingredient contained therein and has high stability so that the production of any decomposition product can be prevented during storage. An adhesive patch for external applications, comprising a support and an adhesive agent layer arranged on the support and containing 0.1 to 10 wt% of loxoprofen sodium, wherein the adhesive agent layer comprises 5 to 30 wt% of a styrene-isoprene-styrene block copolymer, 10 to 50 wt% of an alicyclic saturated hydrocarbon resin, 0.1 to 1 wt% of lactic acid and 5 to 15 wt% of a higher fatty acid and the ratio of the content of lactic acid to the content of the higher fatty acid (i.e., (lactic acid)/(higher fatty acid)) is 1/50 to 1/5.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
77.
ADHESIVE SKIN PATCH CONTAINING SEROTONIN RECEPTOR ANTAGONIST DRUG
Provided is a transdermally absorbable adhesive skin patch containing a serotonin receptor antagonist drug, which has a short transdermal absorption lag time, and in which the maximum skin permeability rate of the drug can be reached within a short time and the drug can disappear from circulating blood rapidly. That is, provided is an adhesive skin patch comprising: an adhesive agent layer comprising a non-functional acrylic adhesive agent, a water-soluble organic amine and a fatty acid ester; and a serotonin receptor antagonist drug such as granisetron which is contained in the adhesive agent layer as a pharmacologically active ingredient.
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61P 1/08 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des nausées, du mal des transports ou des vertigesAntiémétiques
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
Provided is a water-based patch that contains ketoprofen as an active ingredient, provides high transdermal absorbability of the ketoprofen, and has high safety and high storage stability. The water-based patch contains the ketoprofen, an amine, and polyethylene glycol. In the water-based patch, the added amount of the ketoprofen in a paste is 0.1 to 5% by weight, the added amount of the amine in the paste is 0.5 to 10% by weight, and the added amount of the polyethylene glycol in the paste is 5 to 30% by weight. Particularly, in the water-based patch, diisopropanolamine is used as the amine.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
The present invention provides an electrode device used in iontophoresis treatment, in which an electrode layer used for introduction of medication can be contacted to a medication reservoir layer with a simple manner, and in which the medication reservoir layer can be reliably held when the medication is introduced into a skin. A main-electrode layer 3 and a sub-electrode layer 1 are secured on a substrate 6 while both the layers are being insulated from each other. The main-electrode layer 3 is intended for introduction of the medication, and the sub-electrode layer 1 is provided to hold the medication reservoir layer 5 on the substrate 6. The medication reservoir layer 5 is located on the substrate 6, so as to be in contact with the main-electrode layer 3 and the sub-electrode layer 1. The medication reservoir layer 5 is a gel containing halogen compound, and the sub-electrode layer 1 comprises a metal having a lower ionization tendency than hydrogen. The medication reservoir layer 5 and the sub-electrode layer 1 are bonded to each other by applying an electric current to both layers. In this way, the medication reservoir layer 5 can be firmly held on the substrate 6, while being kept in contact with the main-electrode layer 3.
An adhesive patch is provided in which piroxicam is formulated as a non-steroidal anti-inflammatory analgesic. In particular, provided is a piroxicam-containing transdermally absorbable adhesive patch in which an absorption promoter to piroxicam is formulated to achieve high anti-inflammatory and analgesic effects without inhibiting releasing of these drugs. The piroxicam-containing transdermally absorbable adhesive patch contains piroxicam as a medicinal component and oxybuprocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In the piroxicam-containing transdermally absorbable adhesive patch, the content of piroxicam is from 0.1% to 5% by weight to the total weight of a drug-containing plaster and the content of oxybuprocaine or the pharmaceutically acceptable salt thereof is from 1% to 30% by weight to the total weight of the drug-containing plaster.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 31/245 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro du type acide aminobenzoïque, p. ex. procaïne, novocaïne
An iontophoresis patch is equipped with a donor gel and a reference gel which are disposed to contact an external conductor, for example, the skin of a patient and thereby output current from a current-carrying device to the external conductor. The iontophoresis patch includes: a donor portion having the donor gel containing a medical agent to be penetrated into the external conductor; a reference portion having a reference gel, mounted with the current-carrying device on the surface on the side opposite to the reference gel, and disposed on the external conductor apart from the donor portion; and an electrode film for supplying current from the current-carrying device to the donor gel and the reference gel.
An external patch containing diclofenac hydroxyethylpyrrolidine prepared by laminating an adhesive layer on a backing, wherein said adhesive layer is characterized by comprising 5-50% by weight of styrene•isoprene•styrene block copolymer, 20-50% by weight of a tackifier resin, 5-70% by weight of a softening agent, and 0.5-20% by weight of one or more solubilizers selected from N-methyl-2-pyrrolidone, propylene glycol and dimethyl sulfoxide as essential ingredients, and 0.5-20% by weight of diclofenac hydroxyethylpyrrolidine as an active ingredient. The patch has excellent transdermal absorption, less skin-irritation and excellent stability of the drug.
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Cosmetics; cosmetic preparations; adhesives for cosmetic
purposes; cosmetic masks; soaps; perfumery; essential oils;
hair lotions. Pharmaceuticals; pharmaceutical preparations, compositions,
creams and/or lotions; prescription and over-the-counter
pharmaceutical preparations; prescription and
over-the-counter pharmaceutical preparations, namely,
transdermal gel formulations, transdermal cream
formulations, oral mucous formulations, transdermal patches,
dressings and medical adhesive tapes for use in the
treatment of cardiovascular conditions, allergies, central
nervous system conditions, peripheral nervous system
conditions, electrolytic imbalance, caloric imbalance,
obesity, vitamin imbalance, gastrointestinal conditions,
inflammation, dermatological conditions, infectious
diseases, hormonal imbalance, pain, cancer conditions,
pulmonary conditions, ophthalmic conditions, musculoskeletal
conditions, diabetic conditions, psychosis, senile
conditions, dementia, congenital disease conditions,
abnormal gene conditions. Pharmaceutical research and development; pharmaceutical
product evaluation, testing and/or inspection services;
providing medical and scientific research information in the
field of pharmaceuticals; information, advisory and
consultancy services relating to all the aforesaid services.
An aqueous patch containing diclofenac sodium, wherein the patch contains a homogeneous mixed solution of diclofenac sodium, wherein the solution is obtained by mixing crotamiton, diclofenac sodium and water in the mixture ratio of crotamiton/diclofenac sodium of 8.0 or less and the mixture ratio of (water+crotamiton)/diclofenac sodium of 3.0-20.0.
A61K 8/03 - Compositions liquides avec au moins deux couches distinctes
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
Provided is a donepezil-containing transdermal absorption formulation that can sustainably administer donepezil for a long period of time, and can provide both a rapid increase in the blood level of donepezil and donepezil sustained release properties. The donepezil-containing transdermal absorption formulation is a transdermal absorption formulation produced by dissolving donepezil, which is the active ingredient, in an adhesive patch base that contains a hydrophobic polymer and an absorption promoter. The absorption promoter is one kind or two or more kinds selected from lauryl alcohol, triethyl citrate, isopropyl myristate, cetyl lactate, oleyl alcohol, sorbitan monooleate, polyethylene glycol monostearate, lauromacrogol, N-methyl-2-pyrrolidone, and triacetin.
It is an object of the present inventions to produce a pharmaceutical composition for the iontophoresis wherein a drug stability is excellent, and it is easy to blend and fill up when manufactured and it is possible to manufacture at low cost. A pharmaceutical composition for an iontophoresis according to the present invention, is characterized in that the composition contains a nonionic synthetic polymer, betamethasone sodium phosphate and solvent. Furthermore, in a preferred embodiment of a pharmaceutical composition for an iontophoresis according to the present invention, the composition is characterized in that the nonionic synthetic polymer is polyvinyl alcohol (PVA). Furthermore, in a preferred embodiment of a pharmaceutical composition for an iontophoresis according to the present invention, the composition is characterized in that the mixing amount of the polyvinyl alcohol (PVA) is 0.5 to 30.0 percent by weight.
The present invention verifies a method for alleviating dermal irritation (in particular, cumulative dermal irritation) when a local anesthetic is administered by transdermal iontophoresis, and provides an electrode pad imparting greater safety, not only during single-dose administration but also during repeated-dose administration, for pain relief of pain upon injection. An iontophoresis electrode pad comprises: a sheet base material (1); an electrode (3) disposed above the sheet base material; an adhesive sheet (2) provided with an opening, the adhesive sheet being disposed above the sheet base material in a state where the electrode is exposed within the opening; and a drug reservoir (4) containing a local anesthetic, the drug reservoir being disposed in a state of contact with the electrode within the opening of the adhesive sheet. The present invention avoids contact with the skin in a state where the inner peripheral surface of the opening of the adhesive sheet (2) and the outer peripheral surface of the drug reservoir (4) are abutting, and thereby provides relief for dermal irritation.
Provided is a felbinac-containing external patch that shows a high drug release property and also low skin irritation, and is capable of exerting high drug stability. This felbinac-containing external patch is characterized in that L-menthol is not contained, and felbinac having an average particle size of 5 µm or more but less than 100 µm is dispersed to mix with an adhesive base that is composed of styrene-isoprene-styrene block copolymer, alicyclic saturated hydrocarbon resin, softener, and diethyl sebacate, specifically, 0.1 to 10% by weight of felbinac having an average particle size of 5 µm or more but less than 100 µm is dispersed to mix with an adhesive base that is composed of 10 to 30% by weight of styrene-isoprene-styrene block copolymer, 10 to 50% by weight of alicyclic saturated hydrocarbon resin, 10 to 75% by weight of softener, and 0.1 to 10% by weight of diethyl sebacate.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Topical patch preparations that contain an odorless physiological cooling agent, and methods for using the same are provided. The subject topical patch preparations are made up of an adhesive gel composition that is present on a support, where the adhesive gel composition includes the odorless physiological cooling agent, a water-soluble polymer gel, water and a water holding agent. In using the subject topical patch preparations, the topical patch preparations are applied to a skin surface of a subject and maintained at the site of application for a period of time sufficient for an effective amount of the an odorless physiological cooling agent to be administered to the subject. The subject invention finds use in a variety of applications.
Disclosed is a fentanyl-containing adhesive preparation for external use, wherein an adhesive layer is laminated on a supporting body. The adhesive layer contains SIS, a tackifier resin that is composed of a rosin resin and terpene resin, and a softener that is composed of a plybutene and a liquid paraffin. The adhesive layer also contains fentanyl as an active ingredient. The fentanyl-containing adhesive preparation for external use has excellent skin permeation of fentanyl and high preparation stability, without suffering from crystallization of fentanyl during storage.
Wound bed preparation can be performed in a skin wound part by using a hydrogel sheet, said hydrogel sheet comprising a double-layered laminate film, which consists of a polyurethane film and a hydrophobic fiber, and a hydrogel, which contains a water-soluble polymer, glycerol and water and is spread on said laminate film, and having a moisture permeability of 200-2000 (g/m2/24 h).
Disclosed is a substrate of a three-layer structure which is composed of an inner fibrous layer for holding a plaster thereon, a film layer having through-holes formed therein, and an outer fibrous layer which has air permeability and with which the plaster or a liquid component that has oozed out from the plaster is prevented from leaking out. Also disclosed is a water-containing adhesive patch obtained using the substrate, the adhesive patch being wearable for a long period.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
Disclosed is a patch support for a water-based plaster having the following structure, said patch support having excellent plaster-holding properties and excellent water-holding properties, inhibiting the sublimation of a drug to improve the long-lasting drug effect, imparting neither restricted feeling nor roughness to a wearer due to the thinness and good flexibility thereof, and having controlled moisture-permeability and little stickiness to thereby comfort the wearer. The patch support for a water-based plaster is a laminate consisting of three layers laminated together, i.e., a non-woven fabric layer (A), a non-woven fabric layer (B) and a film layer having through holes, said film layer being positioned between the non-woven fabric layers (A) and (B), wherein said film layer is formed of a resin comprising an olefin-based elastomer, and said through holes have an area of 0.02-0.18 mm2 per hole and a porosity of 1-10%.
A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p. ex. polyphosphates inorganiques
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer. In some instances, the matrix further includes a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
Local anesthetic emulsion compositions are provided. The local anesthetic emulsion compositions may include: an oily phase comprising a eutectic mixture of a local anesthetic and an acyclic amide; a surfactant; and an aqueous phase. Also provided are methods of making and using the emulsions.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A01N 25/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles
C40B 40/00 - Bibliothèques en soi, p. ex. matrices, mélanges
Disclosed is an aqueous adhesive skin patch which contains ketoprofen as an active ingredient, can keep excellent transdermal absorbability and safety of ketoprofen, and has high storage stability. Specifically disclosed is an aqueous adhesive skin patch characterized by containing ketoprofen, an amine and polyethylene glycol, wherein the contents of ketoprofen, the amine and polyethylene glycol in an ointment thereof are 0.1 to 5 wt%, 0.5 to 10 wt% and 5 to 30 wt%, respectively, and wherein diisopropanol amine is used as the amine.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Provided is an iontophoresis patch. The iontophoresis patch (10) is equipped with a donor gel (30) and a reference gel (34) which are disposed to contact an external conductor, for example, the skin of a patient and thereby output current from a current-carrying device (14) to the external conductor. The iontophoresis patch (10) includes: a donor portion (16) having the donor gel (30) containing a medical agent to be penetrated into the external conductor; a reference portion (18) having a reference gel (34), mounted with the current-carrying device (14) on the surface on the side opposite to the reference gel (34), and disposed on the external conductor apart from the donor portion (16); and an electrode film (20) for supplying current from the current-carrying device (14) to the donor gel (30) and the reference gel (34).
A ketoprofen-containing aqueous patch is provided in which not only operational efficiency in producing is improved, but also the aqueous patch has excellent storage stability and transdermal absorption of ketoprofen. The ketoprofen lysine salt-containing aqueous patch includes a backing layer and an adhesive (paste) layer laminated thereon. The aqueous patch includes as a main active ingredient a ketoprofen lysine salt completely dissolved in a paste including not glycerin but a polyethylene glycol having an average molecular weight of 1000 or less. In the ketoprofen lysine salt-containing aqueous patch, the polyethylene glycol having an average molecular weight of 1000 or less is one or more polyethylene glycols selected from the group consisting of Polyethylene glycol 200, Polyethylene glycol 400, Polyethylene glycol 600, and Polyethylene glycol 1000.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
Disclosed is a diclofenac hydroxyethyl pyrrolidine-containing adhesive patch for external use, which is an adhesive patch obtained by arranging an adhesive layer on a supporting body. The diclofenac hydroxyethyl pyrrolidine-containing adhesive patch for external use is characterized in that the adhesive layer contains, as essential components, 5-50% by weight of a styrene-isoprene-styrene block copolymer, 20-50% by weight of a tackifier resin, 5-70% by weight of a softening agent and 0.5-20% by weight of one or more dissolving agents selected among N-methyl-2-pyrrolidone, propylene glycol and dimethyl sulfoxide, while containing 0.5-20% by weight of diclofenac hydroxyethyl pyrrolidine as an active ingredient. The diclofenac hydroxyethyl pyrrolidine-containing adhesive patch for external use has excellent percutaneous absorption, little skin irritation, and excellent main medicinal ingredient stability.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
